Better Therapeutics, Inc. (BTTX) Research

Better Therapeutics, Inc. specializes in creating innovative software-driven prescription digital therapeutics (PDTs) platforms, primarily for the U.S. market. These advanced therapies are developed to manage and treat various cardiometabolic ailments, such as diabetes and heart disease. Their flagship investigational product, BT-001, is a PDT platform that employs digitally delivered Nutritional Cognitive Behavioral Therapy (NCBT) to address type 2 diabetes. The company's development pipeline further includes BT-002, a PDT designed to assist patients with hypertension in controlling their blood pressure, and BT-003, another PDT focused on helping individuals with hyperlipidemia optimize their cholesterol levels. Established in 2015, Better Therapeutics, Inc. operates from its headquarters in San Francisco, California.

Market snapshot

Symbol
BTTX
Price
$0.00
Day change
0.00%
Market cap
$5.5K
P/E ratio
-0.00x
52-week range
0.0001-0.001
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Ampio Pharmaceuticals, Inc. (AMPE)
  • Arno Therapeutics, Inc. (ARNI)
  • Baudax Bio, Inc. (BXRXQ)
  • Calithera Biosciences, Inc. (CALA)
  • Kaleido Biosciences, Inc. (KLDO)
  • Oncology Pharma Inc. (ONPH)
  • Panacos Pharmaceuticals, Inc. (PANC)
  • SpectraScience, Inc. (SCIE)

Recent insider activity

  • PERRY DAVID P — A-Award (839895 shares) on 2024-02-09
  • PERRY DAVID P — A-Award (1471453 shares) on 2024-01-09
  • PERRY DAVID P — A-Award (3750 shares) on 2023-12-18
  • Carmona Richard H — A-Award (3750 shares) on 2023-12-18
  • LAVIZZO-MOUREY RISA J — A-Award (3750 shares) on 2023-12-18

Open Better Therapeutics, Inc. (BTTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.